Viva Biotech Holdings disclosed that the company repurchased a cumulative 13.91 million ordinary shares on the Hong Kong Stock Exchange between 8 May and 22 May 2026. All repurchased shares are earmarked for cancellation but had not yet been cancelled as of 22 May 2026, leaving the issued share count unchanged at 2.13 billion shares.

The 11 on-market transactions were executed within a volume-weighted average price range of HKD 1.39–1.57 per share. The most recent trade on 22 May 2026 involved 493,500 shares at prices between HKD 1.38 and HKD 1.39, representing a cash outlay of HKD 0.69 million.

The buybacks were carried out under the share-repurchase mandate approved on 12 June 2025, which authorises Viva Biotech to repurchase up to 212.84 million shares. To date, 13.91 million shares have been utilised under this mandate, equivalent to 0.65 % of the company’s issued shares at the time the mandate was granted.

In line with Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on new share issues or treasury-share sales until 21 June 2026.

With all repurchased shares still pending cancellation, Viva Biotech’s issued share capital remains at 2,129.88 million ordinary shares, and the company held no treasury shares as of the disclosure date.